Examples include PIK3CA (26%) and TP53 (13%) mutations in breast cancer; APC (11%), BRAF (10%), KRAS (38%), PIK3CA (11%) and TP53 (9%) mutations in colorectal cancer, and EGFR (12%), KRAS (23%) and STK11 (8%) mutations in lung cancer. This evidence concerns the gene BRAF and breast carcinoma.